Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$23.69 USD
-0.40 (-1.64%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $23.68 -0.01 (-0.04%) 6:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Viking Therapeutics, Inc. has a market cap of $2.71B, which represents its share price of $24.09 multiplied by its outstanding shares number of 112.44M. As a mid-cap company, VKTX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VKTX 23.69 -0.40(-1.64%)
Will VKTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Where Does VKTX Stock Stand After the Obesity Pill Setback?
Other News for VKTX
VKTX forms Stochastic Reached Oversold on September 15
VKTX's price falls by 3.61% on September 12, though its technical setup remains stable.
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
SA Asks: Which biotechs could be acquired by year's end?
Is VKTX building bearish momentum? 180 Bearish Setup shows up after declining 0.5%